Terpene-Enriched Cannabinoid Composition Stabilizing Volatiles

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Cannabis products often have low terpene content due to processing, which affects the functionality and bioavailability of cannabinoids, as terpenes are volatile and lost during drying, storage, and decarboxylation, leading to a relative imbalance in their therapeutic effects.

Innovation Solution

A therapeutic product comprising at least one cannabinoid, one primary terpene, and a non-cannabinoid, non-terpene carrier like cellulose, with a terpenes to cannabinoids weight/weight ratio of 0.1 to 1.0, enhancing the therapeutic effect compared to products with the same cannabinoids and half the amount of terpene.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cannabis plant material is processed through drying, storage, and decarboxylation, then cannabinoids are activated and converted to their active forms, but terpenes are lost due to their volatile nature and evaporation during these processes

Engineering Contradiction:
Improvecannabinoid activationVSAvoidterpene content
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The patent applies preliminary action by adding terpenes to the cannabis composition before the decarboxylation process. This ensures that terpenes are present in the final product despite the high-temperature processing required to activate cannabinoids. The terpenes are incorporated into the composition in advance, protecting them from complete loss during subsequent heating and drying processes.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If terpenes are preserved in cannabis products, then therapeutic effects and bioavailability are enhanced, but processing complexity increases due to the need to prevent terpene evaporation

Engineering Contradiction:
Improvetherapeutic effectVSAvoidprocessing complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by modifying the terpene-to-cannabinoid weight ratio parameter in the composition. By establishing specific ratio ranges (0.1:1 to 1.0:1), the patent optimizes therapeutic effects without requiring complex processing equipment. This parameter-based approach simplifies manufacturing while ensuring adequate terpene content for enhanced bioavailability and therapeutic outcomes.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If terpene content is increased in cannabis products, then aroma and therapeutic functionality are improved, but stability during storage decreases due to terpene volatility

Engineering Contradiction:
Improvearoma and therapeutic functionalityVSAvoidterpene stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies composite materials by creating a multi-component composition that includes cannabinoids, terpenes, and carrier substances. This composite structure allows terpenes to be stabilized within the matrix of other components during storage. The combination of different substances creates a more stable system where terpene volatility is reduced while maintaining aromatic and therapeutic properties.

Inventive Principle:
Principle #40Composite materials

Data Source

PatentUS11628156B2Terpene-enriched cannabinoid composition and method of treatment
Publication Date: 2023.04.18 BUZZELET DEV & TECH LTD

AI summary

Provided is a therapeutic product comprising at least one cannabinoid; at least one primary terpene; and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also provided is a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene. Further provided is a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.